Scion Team Page Image


United by our conviction in the power of therapeutic innovation to improve human health.

Meet the Scion team

The ten companies our team has been part of founding or building over the past ten years have realized uncommon success and, together, have given rise to >15 clinical-stage therapeutics, advanced six promising therapeutics into pivotal clinical trials and have generated >$14 billion in combined public equity value and announced M&A proceeds. We are excited to discover what the future holds.

AL 0014 Hayden

Andreas Loew, PhD


Andreas is a Partner at Scion. He is a 20+-year industry veteran, with protein engineering and structural biology expertise at large and small pharma. Before joining the firm, he was the founder and CSO of Marengo Therapeutics, a developer of transformational protein therapeutics targeting TCRvβ chains for cancer. Previously, he led New Technologies for Biologics at Novartis, heading a research group responsible for the discovery and development of complex biologics, cell, gene and nucleic acid therapies.

In addition to discovering many innovative protein therapeutics, he was the principal inventor of core technologies that established Novartis’ adoptive T-cell therapy portfolio that ultimately led to the first FDA-approved CAR-T product, Kymriah. At Abbott Laboratories, he was instrumental in solving the crystal structure of Humira bound to its target TNF. Andreas is an inventor on >450 patents and patent applications.

Andreas received his Ph.D. in Germany at the University of Bayreuth followed by post-doctoral education in biochemistry and structural biology at the University of Illinois, Birkbeck College London and UT Southwestern Medical Center, Dallas TX. He received the prestigious Novartis VIVA award for his many contributions to the life sciences.